case_images: PMC11810147_01
case_images: Blood glucose variability before, during, and after CFII implementation.. Blood glucose levels fluctuated significantly during the pre-CFII phase (intensive insulin therapy, Day 2-3), ranging from 38 to 361 mg/dL. Following the initiation of Continuous Feeding Insulin Injection (CFII) on Day 3, blood glucose variability progressively decreased, with further stabilization from Day 4 onwards. During the post-CFII phase (Day 8-10), blood glucose fluctuations increased again, demonstrating a return to the pre-CFII instability pattern. CFII was effective in reducing glucose variability and preventing hypoglycemia.
case_images: cureus-0017-00000078758-i01.jpg
case_images: PMC11810147_01_cureus-0017-00000078758-i01.jpg
case_images: FIG1
case_images: Following the initiation of CFII on Day 3, blood glucose variability progressively decreased (Figure 1). However, during this phase, blood glucose variability increased again, with pre-meal and post-meal BG values fluctuating between 84-301 mg/dL (Figure 1).
case_images: Mean blood glucose levels and standard deviation across treatment phases.. The mean+-SD blood glucose levels during the pre-CFII phase (intensive insulin therapy, Day 2-3) were 218.6+-110 mg/dL, indicating poor glycemic control. With the implementation of CFII (Day 3-7), mean blood glucose levels improved to 164.5+-35.9 mg/dL, with further stabilization from Day 4 onwards (162.8+-31.7 mg/dL). In the post-CFII phase (Day 8-10), mean blood glucose levels increased to 214.5+-60.7 mg/dL, demonstrating greater variability and reinforcing the efficacy of CFII in stabilizing glucose levels compared to conventional insulin therapy.
case_images: cureus-0017-00000078758-i02.jpg
case_images: PMC11810147_01_cureus-0017-00000078758-i02.jpg
case_images: FIG2
case_images: The mean+-SD of blood glucose during this period was 218.6+-110 mg/dL, demonstrating poor glycemic control (Figure 2). From Day 4 onwards (Day 4-7), blood glucose variability showed a further tendency to stabilize, with a mean+-SD of 162.8+-31.7 mg/dL (Figure 2). The mean+-SD blood glucose level during this period was 214.5+-60.7 mg/dL (Figure 2), indicating a significant increase in variability compared to the CFII phase.